Introduction
The fourth international meeting of Innovators in Urology was held this year in March in Miami, USA. There were 43 delegates, both clinicians and scientists with expertise in urologic oncology and specifically prostate cancer, who gathered from 19 countries. The faculty consisted of a mix of internationally renowned urologists and scientists, who shared their considerable experience with the attendees. The diverse programme incorporated for the first time a number of keynote speeches by the faculty amongst them a presentation by Professor Hans Lilja on the role of latent and active forms of kallikrein gene products in progression and detection of prostate cancer while Professor Ralph Buttyan discussed the role of the hypoxia-response in progression of prostate cancer.
Each delegate had a poster presentation. This format provided an opportunity for individual discussions on very specific topics. The scientific content of the posters was extremely high and the topics included: optimisation of prostate biopsy techniques; rapid PSA screening; novel tumour markers; treatment outcomes; and a wealth of new research employing molecular biology to identify new therapeutic modalities for prostate cancer. The details of these research findings plus many other exciting areas of research are contained within this supplement, and reflect the growth in our understanding of prostate cancer. The valuable contributions of these innovators in urology will ultimately allow us to better tackle this disease, whose life-threatening prevalence is ever increasing in the ageing male.
I would like to thank AstraZeneca, on behalf of both the delegates and the faculty members, for their generous ongoing support of this valuable programme, which will undoubtedly provide new insights into future diagnosis and management of prostate cancer.
I look forward with enthusiasm to next year's meeting in The Netherlands.
